系统性血管炎疾病活动度的评估
Assessment of disease activity in systemic vasculitis.
作者信息
Tse W Y, Cockwell P, Savage C O
机构信息
Department of Medicine, CCRIS, Medical School, University of Birmingham, UK.
出版信息
Postgrad Med J. 1998 Jan;74(867):1-6. doi: 10.1136/pgmj.74.867.1.
Abstract
The systemic vasculitides are a group of inflammatory disorders characterised by relapses and remission. Before the introduction of immunosuppressive drugs, mortality was unacceptably high. Immunosuppressive therapy has had a therapeutic impact, but at the cost of increased risk of infection and other adverse effects. Differentiating infection from active disease can be difficult, and the inappropriate prescription of immunosuppressive drugs can be fatal. Hence disease indices which can aid physicians to identify the active phase of disease and enable early treatment, will be valuable in the management of this group of disorders.
摘要
系统性血管炎是一组以复发和缓解为特征的炎症性疾病。在免疫抑制药物引入之前，死亡率高得令人难以接受。免疫抑制疗法产生了治疗效果，但代价是感染风险和其他不良反应增加。区分感染与疾病活动可能很困难，不适当的免疫抑制药物处方可能是致命的。因此，能够帮助医生识别疾病活动期并实现早期治疗的疾病指标，在这组疾病的管理中将具有重要价值。
相似文献
1
Assessment of disease activity in systemic vasculitis.
Postgrad Med J. 1998 Jan;74(867):1-6. doi: 10.1136/pgmj.74.867.1.
2
Assessment of systemic vasculitis.
Autoimmun Rev. 2008 Dec;8(2):170-5. doi: 10.1016/j.autrev.2008.07.001. Epub 2008 Jul 29.
3
Clinical disease activity in systemic vasculitis.
Curr Opin Rheumatol. 1996 Jan;8(1):12-8. doi: 10.1097/00002281-199601000-00002.
4
15. Vasculitis.
J Allergy Clin Immunol. 2003 Feb;111(2 Suppl):S602-12. doi: 10.1067/mai.2003.80.
5
Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection.
Arthritis Rheum. 1997 Jul;40(7):1250-6. doi: 10.1002/1529-0131(199707)40:7<1250::AID-ART9>3.0.CO;2-A.
6
Pooled intravenous immunoglobulin in the management of systemic vasculitis.
Adv Exp Med Biol. 1993;336:469-72. doi: 10.1007/978-1-4757-9182-2_84.
7
Evaluation and treatment of vasculitis in the critically ill patient.
Crit Care Clin. 2002 Apr;18(2):321-44. doi: 10.1016/s0749-0704(01)00006-9.
8
Serum soluble interleukin 2 receptor levels in anti-neutrophil cytoplasmic autoantibodies--positive systemic vasculitis.
Postgrad Med J. 1993 Sep;69(815):708-11. doi: 10.1136/pgmj.69.815.708.
9
Vasculitis.
J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S216-25. doi: 10.1016/j.jaci.2009.07.002. Epub 2009 Nov 24.
10
Correlation of disease activity in systemic vasculitis with serum C-reactive protein measurement. A prospective study of thirty-eight patients.
Eur J Clin Invest. 1985 Apr;15(2):89-94. doi: 10.1111/j.1365-2362.1985.tb00150.x.
引用本文的文献
1
Vascular ultrasound as a follow-up tool in patients with giant cell arteritis: a prospective observational cohort study.
Front Med (Lausanne). 2024 Jul 29;11:1436707. doi: 10.3389/fmed.2024.1436707. eCollection 2024.
2
Glucocorticoid therapy causes contradictory changes of serum Wnt signaling-related molecules in systemic autoimmune diseases.
Clin Rheumatol. 2018 Aug;37(8):2169-2178. doi: 10.1007/s10067-017-3689-3. Epub 2017 May 27.
3
Giant cell arteritis: Current treatment and management.
World J Clin Cases. 2015 Jun 16;3(6):484-94. doi: 10.12998/wjcc.v3.i6.484.
4
Clinical [corrected] and pathological characteristics of Chinese patients with antineutrophil cytoplasmic autoantibody associated systemic vasculitides: a study of 426 patients from a single centre.
Postgrad Med J. 2005 Nov;81(961):723-7. doi: 10.1136/pgmj.2005.034215.
本文引用的文献
1
Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis.
Arthritis Rheum. 1993 Mar;36(3):365-71. doi: 10.1002/art.1780360312.
2
Serum markers of T cell activation in relapses of Wegener's granulomatosis.
Clin Exp Immunol. 1993 Mar;91(3):415-20. doi: 10.1111/j.1365-2249.1993.tb05918.x.
3
Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis.
Arthritis Rheum. 1993 Sep;36(9):1286-94. doi: 10.1002/art.1780360913.
4
Nomenclature of systemic vasculitides. Proposal of an international consensus conference.
Arthritis Rheum. 1994 Feb;37(2):187-92. doi: 10.1002/art.1780370206.
5
Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis.
Arthritis Rheum. 1994 Jun;37(6):919-24. doi: 10.1002/art.1780370622.
6
Relapses in patients with a systemic vasculitis.
Q J Med. 1993 Dec;86(12):779-89.
7
Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.
QJM. 1994 Nov;87(11):671-8.
8
ANCA and predicting relapse in systemic vasculitis.
QJM. 1995 Feb;88(2):127-33.
9
Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients.
Clin Nephrol. 1993 Mar;39(3):125-36.
10
Correlation of blood levels of soluble vascular cell adhesion molecule-1 with disease activity in systemic lupus erythematosus and vasculitis.
Br J Rheumatol. 1994 Dec;33(12):1112-6. doi: 10.1093/rheumatology/33.12.1112.
Zotero 插件